Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype  by Lee, Ji-Hyun et al.
Respiratory Medicine (2010) 104, 542e549ava i lab le a t www.sc iencedi rec t .com
journa l homepage : www.e lsev ie r . com/ loca te / rmedResponses to inhaled long-acting beta-agonist and
corticosteroid according to COPD subtype*Ji-Hyun Lee a, Young Kyung Lee b, Eun-Kyung Kim a, Tae-Hyung Kim c,
Jin Won Huh d, Woo Jin Kim e, Jin Hwa Lee f, Sang-Min Lee g, Sangyeub Lee h,
Seong Yong Lim i, Tae Rim Shin j, Ho Il Yoon k, Seung Soo Sheen l,
NamKug Kim m, Joon Beom Seo m, Yeon-Mok Oh n,*, Sang Do Lee n,**a Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Bundang CHA Hospital,
College of Medicine, CHA University, Seongnam, South Korea
b Department of Radiology, East-West Neo Medical Center, Kyunghee University, Seoul, South Korea
c Division of Pulmonology, Department of Internal Medicine, Hanyang University Guri Hospital,
Hanyang University College of Medicine, Guri, South Korea
d Department of Internal Medicine, Ilsan Paik Hospital, Inje University, Goyang, South Korea
e Department of Internal Medicine, College of Medicine, Kangwon National University, Chuncheon, South Korea
f Department of Internal Medicine, Ewha Womans University Mokdong Hospital, College of Medicine,
Ewha Womans University, Seoul, South Korea
g Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of
Medicine, Clinical Research Institute, Seoul National University Hospital, Lung Institute, Medical Research Center,
Seoul National University College of Medicine, Seoul, South Korea
h Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine,
Korea University Anam Hospital, Seoul, South Korea
i Division of Pulmonary and Critical Care Medicine, Department of Medicine, Kangbuk Samsung Hospital,
Sungkyunkwan University School of Medicine, Seoul, South Korea
j Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine,
Seoul, South Korea
k Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of
Medicine, Seongnam, South Korea
l Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, Suwon, South Korea
m Department of Radiology, and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of
Medicine, Seoul, South Korea
n Department of Pulmonary and Critical Care Medicine, and Clinical Research Center for Chronic Obstructive Airway
Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 388-1 Pungnap-dong, Sonpa-gu,
Seoul 138-736, South Korea
Received 22 June 2009; accepted 28 October 2009
Available online 17 November 2009* Both authors contributed equally to this work with senior responsibilities.
* Corresponding author. Tel.: þ82 2 3010 3136; fax: þ82 2 3010 6968.
** Corresponding author. Tel.: þ82 2 3010 3140; fax: þ82 2 3010 6968.
E-mail addresses: ymoh55@amc.seoul.kr (Y.-M. Oh), sdlee@amc.seoul.kr (S.D. Lee).
0954-6111/$ - see front matter ª 2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.rmed.2009.10.024
Varying responses according to COKEYWORDS
COPD;
Subtype;
Inhaled long acting
bronchodilator;
CorticosteroidSummary
Rationale: Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous
disorder in which a number of different pathological processes lead to recognition of patient
subgroups that may have individual characteristics and distinct responses to treatment.
Objectives: We tested the hypothesis that responses of lung function to 3 months of combined
inhalation of long-acting beta-agonist and corticosteroid might differ among patients with
various COPD subtypes.
Methods: We classified 165 COPD patients into four subtypes according to the severity of emphy-
sema and airflow obstruction: emphysema-dominant, obstruction-dominant, mild-mixed, and
severe-mixed. The emphysema-dominant subtype was defined by an emphysema index on
computed tomography of more than 20% and FEV1 more than 45% of the predicted value. The
obstruction-dominant subtype had an emphysema index 20% and FEV1 45%, the mild-mixed
subtype had an emphysema index 20% and FEV1> 45%, and the severe-mixed subtype had an
emphysema index> 20% and FEV1 45%. Patients were recruited prospectively and treated
with 3 months of combined inhalation of long-acting beta-agonist and corticosteroid.
Results: After 3 months of combined inhalation of long-acting beta-agonist and corticosteroid,
obstruction-dominant subtype patients showed a greater FEV1 increase and more marked
dyspnea improvement than did the emphysema-dominant subgroup. The mixed-subtype
patients (both subgroups) also showed significant improvement in FEV1 compared with the
emphysema-dominant subgroup. Emphysema-dominant subtype patients showed no improve-
ment in FEV1 or dyspnea after the 3-month treatment period.
Conclusion: The responses to 3 months of combined inhalation of long-acting beta-agonist and
corticosteroid differed according to COPD subtype.
ª 2009 Elsevier Ltd. All rights reserved.
PD subtype 543Introduction
Chronic obstructive pulmonary disease (COPD) is a disease
state characterized by airflow limitation that is not fully
reversible and is usually progressive.1 Originally, COPD was
classified into two phenotypes, emphysema and chronic
bronchitis.2 These phenotypes are considered to result
from differences in sensitivity to noxious particles or gases,
especially tobacco smoke, which may affect the develop-
ment of emphysema or airway structural changes.3 The
pathophysiological pathways leading to emphysema and
small airway narrowing are independent4 but interact in
a complex manner. In addition, the relative contributions
toward irreversible airflow limitation caused by patholog-
ical changes in airways, and emphysema, vary among
individuals,5 and most patients with COPD cannot be clearly
classified as showing either phenotype.
Chronic inflammation causes remodeling and narrowing
of small airways, and, theoretically, airflow obstruction at
such sites should respond to pharmacological agents such as
bronchodilators and inhaled corticosteroids (ICS). Destruc-
tion of lung parenchyma leads to the loss of alveolar
attachment to small airways and decreases lung elastic
recoil; these pathological changes are considered to be
unresponsive to pharmacological treatment.
Clinical responses to treatments such as bronchodilators
and/or ICS may therefore vary among individuals according to
the relative contributions of small airway disease and emphy-
sema to airflow limitation. Indeed, significant reversibility of
airflow limitation after use of bronchodilators and/or cortico-
steroids was noted in up to 30% of patients with stable COPD.6
If the severity of emphysema varies in patients showing
the same degree of airflow limitation, it would be possible
to compare drug responses of COPD patients in whom therelative contributions of small airway disease and emphy-
sema differ. Patients displaying little evidence of emphy-
sema despite the presence of severe airflow limitation
might be considered as demonstrating a phenotype in which
small airway disease is predominant.
Therefore, we classified COPD patients into four subtypes
according to the quantitatively evaluated extent of
emphysema on chest volumetric computed tomography (CT)
scans and pre-bronchodilator forced expiratory volume
in 1 second (FEV1) data. We tested the hypothesis that
responses of lung function to 3 months of combined inhala-
tion of a long-acting beta-agonist (LABA) and a corticosteroid
might differ among patients with various COPD subtypes.
Methods
Subjects and data acquisition
A total of 171 COPD subjects were included. The patients
fulfilled all of three criteria, with a post-bronchodilator
ratio of FEV1 to forced vital capacity (FEV1/FVC) of less
than 0.7, more than 10 pack-years of smoking history, and
no or minimal abnormality on chest radiography (Fig. 1).
Among these 171 subjects, 165 patients were analyzed,
because six CT scans were of poor quality.
Before and after the 3-month treatment with combined
inhalation of LABA and corticosteroid, the extent of dysp-
nea (using the modified Medical Research Council [MMRC]
scale7) spirometry data, and lung volume were evaluated in
all patients. During 2 weeks of washout before the 3-month
treatment period, only an inhaled short-acting beta-agonist
(albuterol) was permitted until the day before baseline
data were acquired. During the 3-month treatment period
albuterol was allowed as needed.
Figure 1 Study subjects and the four COPD subtypes. The subtypes of COPD were defined by CT emphysema index and FEV1.
Figure 2 Distributions of FEV1 and CT emphysema index.
Each dot represents data from an individual patient.
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obtained, a 6-minute walk distance (6MWD) test was per-
formed,8 and both diffusing capacity and body mass index
(BMI) were evaluated, in addition to dyspnea scale scoring
and collection of spirometry and lung volume data.
Our Institutional Review Board approved all of the
procedures and written informed consent was obtained
from all patients.
CT emphysema index (EI)
Volumetric CT scans were obtained using a 16-multi-
detector CT (MDCT) scanner (Somatom Sensation instru-
ment; Siemens, Erlangen, Germany; GE Lightspeed Ultra
instrument; General Electric Healthcare; Milwaukee, WI;
Philips Brilliance instrument; Philips Medical Systems, Best,
the Netherlands) as previously described.9 From CT data,
the volume fraction of the lung below 950 Hounsfield
Units (HU) at full inspiration was calculated automatically
and was termed the emphysema index (EI).
Lung function
Spirometry was performed as recommended by the Amer-
ican Thoracic Society (Vmax 22 instrument; SensorMedics,
Yorba Linda, CA; PFDX instrument; MedGraphics, St. Paul,
MN).10 FVC, FEV1, FEV1/FVC, and mean forced expiratory
flow between 25% and 75% of FVC (FEF25e75) were evaluated
before and after inhalation of 400 mg albuterol.
Lungvolume11anddiffusingcapacity12werealsomeasured.
All values are expressed as percentages of predicted values.
COPD subtypes
The emphysema-dominant subtype was defined when EI
was more than 20% and FEV1 was over 45% of the predictedvalue; obstruction-dominant subtype patients had EI 20%
and FEV1 45% predicted; mild-mixed subtype patients had
EI 20% and FEV1> 45% predicted; severe-mixed subtype
patients had EI> 20% and FEV1 45% predicted (Fig. 2).
Cut-off values for EI and FEV1 were determined arbitrarily,
and were close to the median values.
Three-month treatment with combined inhalation
of long-acting beta-agonist and corticosteroid
Among the 165 participants, 147 patients (89%) had been
treated twice daily for 3 months with a combination of
salmeterol (50 mg) and fluticasone propionate (500 mg), and
18 (11%) had been treated twice daily with a combination of
formoterol (9 mg) and budesonide (320 mg). Ninety-one
percent of subjects indicated that they had taken over 80%
of the recommended medication dose.
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All statistical analysis was performed using a statistical
package (SPSS version 12.1.1; SPSS, Chicago, IL). All results
are expressed asmeans standard deviations. Data from the
four groups were compared by one-way analysis of variance
(ANOVA), followed by multiple comparisons using the
Bonferroni post-hoc test. Simple correlations between vari-
ables were examined by Spearman correlation analysis. A P
value less than 0.05 was considered statistically significant.
Results
Baseline characteristics of patients
Most patients had moderate-to-severe COPD according to
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines. Of these, 1% were classified as GOLD 1
(mild COPD), 36% as GOLD 2 (moderate COPD), 48% as GOLD
3 (severe COPD), and 15% as GOLD 4 (very severe COPD).
Patients were classified into four subtypes according to
EI values on CT scans and FEV1 data. Fifty-one patients
were classified as mild-mixed, 31 as emphysema-dominant,
30 as obstruction-dominant, and 53 as severe-mixed
subtypes.
There was no death during the follow-up period. Five
patients of both the mild-mixed and emphysema-dominant
subtypes, four of the obstruction-dominant subtype, and six
of the severe-mixed subtype, dropped out during follow-up.
Thus, a total of 145 patients completed the study (Figs. 1
and 2).
The subjects consisted primarily of elderly patients
(Table 1). The mean ages of the four subtypes of COPD
patients were similar; no significant difference was
apparent. Of all patients, 28e39% were current smokers.
Smoking history, as measured by pack-years, was highest in
the emphysema-dominant subgroup. Body mass index was
lower in the emphysema-dominant and severe-mixed
subgroups than in the mild-mixed or obstruction-dominant
subgroups. The 6MWD was lower in the severe-mixed
subgroup than in the mild-mixed or obstruction-dominant
subgroups, and the MMRC dyspnea scale was higher in the
severe-mixed subgroup than in the mild-mixed subgroup.
The EI was lowest in the emphysema-dominant subgroup
and lower in the severe-mixed subgroup than in the mild-
mixed or obstruction-dominant subgroups.
FEV1 values were lower in the obstruction-dominant and
severe-mixed subgroups than in the mild-mixed or emphy-
sema-dominant subgroups. FVC values were lowest in the
obstruction-dominant subgroup and lower in the severe-
mixed subgroup than in the mild-mixed or emphysema-
dominant subgroups. FEV1/FVC ratios were lowest in the
severe-mixed subgroup, and lower in the emphysema-
dominant and obstruction-dominant subgroups than in the
mild-mixed subgroup. Bronchodilator response after short-
acting beta-agonist inhalation showed no differences
among subgroups. The diffusing capacity (DLCO) was lower
in the emphysema-dominant and severe-mixed subgroups
than in the mild-mixed or obstruction-dominant subgroups.
The obstruction-dominant subgroup also showed a lower
DLCO value than did the mild-mixed subgroup. Total lungcapacity (TLC) was highest in the severe-mixed subgroup
compared with the other three subgroups. Inspiratory
capacity (IC) was lower in the obstruction-dominant and
severe-mixed subgroups than in the mild-mixed and
emphysema-dominant subgroups. Residual volume (RV) was
higher in the obstruction-dominant and severe-mixed
subgroups than in the mild-mixed and emphysema-domi-
nant subgroups.
Responses in lung function and dyspnea scores from
baseline, after 3 months of treatment with long-
acting beta-agonist plus inhaled corticosteroid
The FEV1 response after 3 months of treatment was signifi-
cantly different among COPD subtype patients (Table 2). The
emphysema-dominant subgroup showed the smallest
improvement in FEV1 (0.032 0.263 liters) after 3 months
of treatment, compared with the other three subgroups.
The improvement in FEV1 after 3 months of treatment
was greatest in the obstruction-dominant subgroup
(0.207 0.223 liters) and the two mixed subgroups also
showed intermediate but significant improvements in FEV1
after 3months of treatment, comparedwith theemphysema-
dominant subgroup. There was no statistically significant
difference among the obstruction-dominant and the two
mixed subgroups. After 3 months of treatment, RV was
significantly decreased in theobstruction-dominant subgroup
compared with the mild-mixed and emphysema-dominant
subgroups. Responses of other lung volume parameters after
3 months of treatment showed no significant differences
among subgroups. The MMRC dyspnea score significantly
decreased (patients thus improved) in the obstruction-
dominant subgroup compared with the emphysema-
dominant subgroup.
Correlation between baseline variables and changes
in FEV1 or dyspnea scores after 3 months of
treatment with combined long-acting beta-agonist
plus inhaled corticosteroid in patients with COPD
The change in FEV1 after 3 months of treatment showed
significant but weak correlations with pre-bronchodilator
FEV1 and DLCO values, with correlation coefficients
(r values) of 0.201 and 0.195, respectively. A better
correlation was noted between the change in FEV1 after
3 months of treatment and bronchodilator responses at
baseline (rZ 0.37, p< 0.001, Fig. 3). There was no signif-
icant correlation between change in FEV1 and EI. Changes
in the MMRC score showed weak correlation with EI
(rZ 0.174, pZ 0.038), indicating that patients with lower
EI values experienced more dyspnea relief (a greater
negative value) after 3 months of treatment (Table 3).
Discussion
In the present study, we classified stable COPD patients into
four subtypes according to EI value measured by CT scans,
and FEV1 measured by spirometry. Following 3 months of
combined LABA and ICS treatment, emphysema-dominant
patients showed the smallest improvement in FEV1
Table 1 Baseline characteristics of COPD patients.
Subtype Mild-mixed Emphysema-dominant Obstruction-dominant Severe-mixed
Number of patients 46 26 26 47
Age, years 65.8 8.2 68.0 7.4 65.4 5.3 66.2 7.0
Male 46 (100%) 26 (100%) 25 (96%) 46 (98%)
Smoking, pack-years 43.0 20.0 60.1 436.2* 43.6 19.8x 46.0 22.4{
Current smokers [n, (%)] 18 (39%) 9 (35%) 10 (39%) 13 (28%)
BMI, kg/m2 24.7 3.1 21.7 2.8* 23.9 3.7x 21.6 3.4z**
6MWD, meters 464.3 70.5 434.5 84.0 458.0 54.1 404.5 88.3z**
MMRC score 1.32 1.10 1.58 0.95 1.77 1.00 2.04 1.00z
Emphysema index 9.1 5.7 33.1 9.9* 10.2 6.0x 37.3 10.2z{**
FEV1, liters
(% predicted)
1.93 0.43
(61.0 10.4)
1.66 0.33
(57.2 10.1)
1.11 0.20yx
(37.3 6.0yx)
1.00 0.27z{
(32.3 7.3z{**)
FVC, liters
(% predicted)
3.67 0.75
(83.4 14.0)
3.48 0.71
(86.1 15.8)
2.51 0.59yx
(61.4 13.8yx)
2.86 0.63z{**
(71.0 15.2z{**)
FEV1/FVC, % 53.0 7.8 48.2 7.0* 45.3 8.3y 34.1 7.6z{**
BDR, mL
(%)
194 156
(5.98 4.63)
147 136
(5.04 4.68)
207 171
(6.77 5.46)
163 125
(5.28 4.06)
DLCO, % predicted 98.5 24.5 65.8 14.7* 85.6 27.5yx 61.2 20.8z**
TLC, liters
(% predicted)
6.40 0.95
(110.1 12.7)
6.50 1.17
(125.5 23.7*)
6.37 1.67
(120.3 36.6)
7.16 1.219z{**
(128.6 19.6z)
IC, liters
(% predicted)
2.37 0.52
(86.3 18.2)
2.18 0.56
(88.9 21.8)
1.73 0.37yx
(68.2 12.3yx)
1.69 0.48z{
(64.2 16.5z{)
RV, liters
(% predicted)
2.64 0.78
(122.0 34.5)
2.96 1.13
(139.4 51.2)
3.69 1.59yx
(179.5 78.9yx)
4.01 1.26z{
(185.6 58.0z{)
6MWD, 6-minute walk distance; BDR, bronchodilator response; BMI, body mass index; DLCO, carbon monoxide diffusing capacity; FEV1,
forced expiratory volume in 1 sec; FVC, forced vital capacity; IC, inspiratory capacity; MMRC, modified Medical Research Council
dyspnea score; RV, residual volume; TLC, total lung capacity.
Data are shown as means standard deviations.
* Mild-mixed vs. Emphysema-dominant, p< 0.05.
y Mild-mixed vs. Obstruction-dominant, p< 0.05.
z Mild-mixed vs. Severe-mixed, p< 0.05.
x Emphysema-dominant vs. Obstruction-dominant, p< 0.05.
{ Emphysema-dominant vs. Severe-mixed, p< 0.05
** Obstruction-dominant vs. Severe-mixed, p< 0.05.
546 J.-H. Lee et al.compared with those of the other three subgroups.
Improvement in FEV1 after 3 months of treatment was
greatest in the obstruction-dominant subgroup, and the
two mixed subgroups also showed intermediate butTable 2 Responses in lung function and dyspnea score follow
agonist and inhaled corticosteroid.
Subtype Mild-mixed Emphysema-dom
DFEV1, liters
(% predicted)
0.169 0.218
(5.1 6.4)
0.032 0.263*
(0.9 9.3*)
DTLC, liters 0.09 0.52 0.09 0.57
DIC, liters 0.07 0.47 0.22 0.48
DRV, liters 0.20 0.64 0.11 0.85
DMMRC score 0.39 1.02 0.16 0.55
FEV1, forced expiratory volume in 1 sec; IC, inspiratory capacity; MMRC
RV, residual volume; TLC, total lung capacity.
Data are shown as means standard deviations. One-way analysis of v
for multiple comparisons.
* Mild-mixed vs. Emphysema-dominant, p< 0.05.
y Mild-mixed vs. Obstruction-dominant, p< 0.05.
z Mild-mixed vs. Severe-mixed, p< 0.05.
x Emphysema-dominant vs. Obstruction-dominant, p< 0.05.
{ Emphysema-dominant vs. Severe-mixed, p< 0.05.
** Obstruction-dominant vs. Severe-mixed, p< 0.05.significant improvement in FEV1 after 3 months of treat-
ment, compared with the emphysema-dominant subgroup.
Airflow obstruction in the emphysema-dominant subgroup,
as measured by FEV1 and dyspnea scale scores, showed noing 3 months of treatment with combined long-acting beta-
inant Obstruction-dominant Severe-mixed
0.207 0.223x
(6.7 7.3x)
0.155 0.166{
(5.1 5.5{)
0.41 1.11 0.16 0.56
0.11 0.30 0.11 0.33
0.63 1.26yx 0.31 0.77
0.68 1.03x 0.26 0.74
, modified Medical Research Council dyspnea scale measurement;
ariance for quantitative variables with Bonferroni’s test was used
Figure 3 The correlation between bronchodilator response
and change in FEV1 after 3 months of treatment with long-
acting beta-agonist and inhaled corticosteroid (deltaFEV1) was
significant, with a correlation coefficient of 0.37 (p< 0.001).
Bronchodilator response was measured as the increase in FEV1
after inhalation of 400 mg albuterol.
Table 3 Correlation between baseline variables and
change in FEV1 or dyspnea scores after 3 months of treat-
ment with combined long-acting beta-agonist plus inhaled
corticosteroid in patients with COPDa.
Baseline variables Change in FEV1 Change in
MMRC score
r value p value r value p value
FEV1, % predicted 0.201 0.015 0.069 0.401
BDRb, mL 0.37 <0.001 0.117 0.164
DLCO, % predicted 0.195 0.019 0.115 0.171
Emphysema index 0.150 0.072 0.174 0.038
BDR, bronchodilator response; DLCO, carbon monoxide diffusing
capacity; FEV1, forced expiratory volume in 1 sec; MMRC,
modified Medical Research Council dyspnea scale measurement;
r, correlation coefficient.
a All patients of the four COPD subtypes were analyzed
together.
b Bronchodilator response was measured as the increase in
FEV1 after inhalation of 400 mg albuterol.
Varying responses according to COPD subtype 547improvement after treatment. Also, the bronchodilator
response after short-acting beta-agonist treatment corre-
lated positively with response after 3 months of treatment
with combined LABA and ICS; although the bronchodilator
response showed no statistically significant difference
among the four subtypes. These findings indicate that the
best treatment response to combined LABA and ICS may be
expected in patients with the airway obstruction-dominant
phenotype of COPD, who show a relatively high degree of
airway reversibility. The worst responses may be expected
in patients with the emphysema-dominant phenotype.
To the best of our knowledge, this is the first study to show
that treatment responses to combined LABA and ICS differ
significantly among patients with various subtypes of COPD.
To date, guidelines for therapy selection have been
based on a one-dimensional scale of disease severity.1 An
important challenge in COPD research is the development of
more powerful, multivariate methods for predicting indi-
vidual outcomes and personal responsiveness to particular
therapies, using clinical and laboratory characteristics.
It is well known that, in a susceptible host, small airway
inflammation primarily contributes to airflow limitation by
narrowing or obliterating the airway lumen and by actively
constricting the airway.4 Patients with chronic bronchitis
showed higher levels of eosinophils and macrophages in
sputum than did normal controls, indicating that chronic
bronchitis reflects an inflammatory sub-phenotype among
patients with COPD.13 These findings may indicate
that bronchodilator and/or anti-inflammatory treatment is
indicated for COPD patients with an airway-dominant
phenotype, but not for those with an emphysema-dominant
phenotype.
Recently, Kitaguchi and colleagues showed that airway
disease-dominant COPD patients, who demonstrated bron-
chial wall thickening on high-resolution CT (HRCT), showed
greater reversibility of airflow limitation in response to
short-acting bronchodilator or ICS treatment compared
with patients with either the mixed form of COPD or
emphysema-dominant patients.14 Thus, recent work hasattempted to divide COPD patients into subgroups and to
analyze clinical between-subgroup differences.14e17
However, the available reports show some inconsistencies
in the description of clinical manifestations, which may be
related to the absence of consensus guidelines for differ-
entiating emphysema-dominant and bronchitis-(airway-)
dominant subtypes of COPD. To date, the modes of differ-
entiation used have been arbitrary, and have thus varied
among reports.14,15,17 The availability of consensus meth-
odology to differentiate COPD subgroups will lead to
a revision of some original concepts of the natural history of
COPD, which will finally enable clinicians to precisely
characterize and understand the disease.
Originally, symptoms of chronic bronchitis were used to
identify a subgroup of COPD patients. According to results
of the Lung Health Study, the prevalence of respiratory
symptoms decreased by 80% after 5 years of smoking
cessation.18 Therefore, many patients with COPD may not
show symptoms of chronic bronchitis even though they also
display little evidence of emphysema. Thus, we did not use
such symptoms as indicators of airway involvement.
Recently, CT has become popular for noninvasive
assessment of airway disease in COPD patients,19e21
particularly with the development of multi-slice CT scanning
techniques. However, CT scans are still limited by a pixel
size of approximately 0.5 mm, which makes measurements
on small airways, in particular, prone to error.22 However,
quantification of emphysema by CT can be objectively per-
formed using computer-based analysis, which has been
validated by pathologic correlation.23e26 One of the major
advantages of computer-based quantification is that the
results are of high reproducibility, because little or no
human intervention is involved. The software used in the
present study was developed by our research group, and has
been validated in our previous study.9
A low attenuation area on CT may reflect hyperlucency
resulting from air trapping, rather than emphysema per se,
thus confounding the assumption that a CT score simply
indicates the extent of emphysema. However, in the
present study, as in many similar studies, EI on CT scan
548 J.-H. Lee et al.correlated well with DLCO, with an r-value of 0.623
(p< 0.001). DLCO is thus another indicator of the degree of
emphysema.17,27
Although diffusing capacity is less sensitive than a CTscan
to diagnose mild emphysema,28 and although diffusing
capacity may decrease in patients with severe airway
obstruction, it may be valuable to assess emphysema and to
divide patients into COPD subtypes using DLCO instead of EI
because CT instruments may not always be readily available.
Therefore, we used DLCO values rather than CT EI to divide
patients into four subgroups using FEV1 and DLCO. With cut-
off values for FEV1 of 45% and for DLCO of 75% (these are the
median values), treatment response expressed as changes in
FEV1 and dyspnea index was similar to the results obtained
using FEV1 and EI analysis (data not shown). Because chest
CT is not routinely used in clinical settings to evaluate
patients with COPD, DLCO may serve as a useful surrogate for
EI in categorization of the four subtypes.
The value of the bronchodilator response after adminis-
tration of short-acting beta-agonists in predicting patient
response after long-acting bronchodilator (and ICS) treat-
ment remains controversial.29e31 However, bronchodilator
response seems to be useful in assessing treatment response
to LABA and/or ICS in patients with COPD. In the present
study, an improvement in FEV1 after 3 months of combined
LABA and ICS treatment correlated positively with broncho-
dilator response after administration of a short-acting beta-
agonist. Considering that the correlation coefficient was
relatively low (rZ 0.37) and that there was no significant
difference in bronchodilator response among subgroups, it
may be unreliable to seek to predict the response to long-
term treatment using only bronchodilator response data.
Because the majority of our COPD patients showed
a mixed form of emphysema and bronchiolitis, and because
the mixed-form subgroup included patients with a wide
range of airflow obstruction, from mild to severe, we
divided patients into four subgroups, including mild-mixed
and severe-mixed. Although FEV1 improved most in the
obstruction-dominant subgroup, the mixed subgroups
showed an intermediate improvement in FEV1, compared
with the emphysema-dominant subgroup. It is important to
note that mild-mixed subgroup patients, with an average
FEV1 value of 61%, also showed a significant FEV1 increase
and dyspnea improvement after treatment, as did the
severe-mixed subgroup. According to GOLD guidelines,
regular treatment with ICS is recommended for symptom-
atic COPD patients with FEV1< 50% of predicted value, who
also show repeated exacerbation.1 However, considering
the similar improvement in lung function and dyspnea in
the two mixed subgroups, and the fact that almost 80% of
patients (excluding the 20% of emphysema-dominant
patients) demonstrated some improvement after treat-
ment, combined LABA and ICS should be considered even
for mild symptomatic COPD patients, especially if there is
little evidence of emphysema.
Our study had some limitations. First, we did not sepa-
rately analyze responses to LABA and ICS because we did
not compare response to the combined LABA/ICS treatment
with the effects of treatment with either LABA or ICS alone.
However, other clinical studies have shown that combined
LABA/ICS treatment may be superior to use of LABA or ICS
alone.32,33Second, we diagnosed and enrolled patients with COPD
using GOLD guidelines,1 although it is known that these
guidelines (airway obstruction that is not fully reversible)
lack precision in differentiating asthma from COPD. It is
difficult to distinguish the two diseases in particular
patients, especially smokers and/or the elderly. Also, the
short-acting bronchodilator response is of limited value in
differentiating between the two conditions. We excluded
doctor-diagnosed asthma patients. To the best of our
knowledge, this is the optimal method for differentiation of
the two diseases in clinical practice.
Finally, our cut-off values for classifying patients into
subgroups were arbitrary. We also used the mean values of
FEV1 and EI, an FEV1 of 50% and an EI of 20%, in statistical
analysis, and found that the principal results of the present
study were not affected by such data manipulation. This
means that even though our subgrouping was somewhat
arbitrary, and although most COPD patients showed a mixed
phenotype of airway obstruction and emphysema, the
relative contribution of emphysema and airway obstruction
in each patient is nonetheless important in the prediction
of response to treatment.
In conclusion, it is important to examine between-
patient differences to determine who will benefit from
bronchodilators and/or ICS treatment. Patient subgrouping
using FEV1 and EI obtained by CT scanning may help to
identify those who will respond to selective therapy. In the
present study, we showed that the response to 3 months of
LABA and ICS treatment varied with COPD subtype.
Obstruction-dominant COPD patients showed the best
response and emphysema-dominant patients the worst.
Further studies on standardized identification of predomi-
nant phenotypes may improve our understanding of
underlying COPD pathophysiology and should facilitate
development of selective treatments for the complex
disease labeled, in an over-simplification, as COPD.Acknowledgement
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